<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879242</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670AIT07</org_study_id>
    <secondary_id>EUDRACT Code :2008-003230-22</secondary_id>
    <nct_id>NCT00879242</nct_id>
  </id_info>
  <brief_title>Effect of Deferasirox on Patients With Cardiac MRI T2* &lt; 20 Msec</brief_title>
  <official_title>Multicenter, Open Label, Prospective Study to Evaluate the Efficacy and Safety of Deferasirox 30 mg/kg/Day for 52 Weeks, in Transfusion-dependent Beta-thalassemic Patients With Cardiac MRI T2* &lt; 20 Msec</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI
      T2* &lt; 20 msec.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cardiac T2* value</measure>
    <time_frame>52 weeks</time_frame>
    <description>Unsatisfactory response is a monthly MRI T2* improvement lower than 3% versus baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac functions parameters (LVEF, LVESV and LVEDV)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline liver T2* value</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Beta Thalassemia Transfusion Dependent</condition>
  <arm_group>
    <arm_group_label>Deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <description>Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.</description>
    <arm_group_label>Deferasirox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  β-thalassemic patients receiving regular transfusions with an history of at least 20
             transfusional events

          -  Patients naïve for deferasirox

          -  Serum ferritin levels ≥1000ng/ml (average of the last 6 months assays);

          -  Cardiac MRI T2* &gt;5 and &lt;20 msec.

          -  LVEF at MRI ≥56%

        Exclusion Criteria:

          -  Patients that have already started deferasirox therapy

          -  Existing contraindications to the performance of MRI procedure, including presence of
             metallic prostheses not compatible with the MRI procedure other than those approved as
             safe for use in MRI scanners (e.g., some types of aneurysm clips, shrapnel in
             proximity to vital organs such as the retina), pacemaker, intractable claustrophobia
             and incapability to follow the instruction for the correct performance of the MRI
             (e.g. to maintain a supine position, to hold breath, etc.)

          -  Clinical conditions requiring intensive chelating therapy on the basis of
             Investigator's judgment

          -  Stable average ALT levels &gt;300 U/L in the preceding 12 months

          -  Uncontrolled systemic hypertension

          -  Estimated creatinine clearance &lt;60 ml/min

          -  History of nephrotic syndrome

          -  History of clinically significant ocular toxicity related to the chelating therapy

          -  Psychiatric disorders or drug dependence that might impair the capability of the
             patient to provide their Informed Consent or to be administered the study treatment

          -  Known sensitivity to study drug(s) or class of study drug(s)

          -  Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study

          -  Use of any other investigational agent in the last 30 days.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7523</url>
    <description>Results for CICL670AIT07 on the Novartis Clinical Trial Results Website</description>
  </link>
  <results_reference>
    <citation>Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. Br J Haematol. 2014 Nov;167(3):423-6. doi: 10.1111/bjh.12987. Epub 2014 Jun 30.</citation>
    <PMID>24976388</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thalassemia</keyword>
  <keyword>cardiac MRI T2*</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

